Jacinthe Leclerc

Jacinthe Leclerc

Auto-generated profile, based on publicly available information

Jacinthe Leclerc

Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Metabolic Syndrome and Related Disorders
Verified
Journal Article
Closed access
PAPelumi Samuel Akinola
Pelumi Samuel Akinola
ITIsabelle Tardif
Isabelle Tardif
JLJacinthe Leclerc
Jacinthe Leclerc
Schizophrenia, a serious psychiatric disorder, is among the top 10 global causes of disability and affects nearly 1% of the world population. Antipsychotics constitute the best treatment for patients with schizophrenia, however, this treatment class carries a high risk of metabolic syndrome, including lipid abnormalities. Indeed, the risk of metabolic syndrome would be increased in the population with schizophrenia compared to the general population. The objective is to summarize the prevalence, the mechanisms, and the potential treatments of antipsychotic-induced metabolic syndrome. This is a narrative review of the literature. We searched the electronic database Medline, accessed through PubMed, to find studies that investigated the prevalence and treatments of metabolic syndrome in the adult population using antipsychotics. The prevalence of metabolic syndrome in patients treated with antipsychotics ranges from 37% to 63%. Antipsychotic iatrogenic effects include weight gain/increased waist circumference, dyslipidemia, insulin resistance/type 2 diabetes, and hypertension. Clozapine and olanzapine are reported to precipitate the onset of metabolic syndrome features. In patients with metabolic syndrome, an antipsychotic with less metabolic side effects such as lurasidone, lumateperone, ziprasidone, and aripiprazole should be prioritized. Unlike medications, aerobic exercise and dietetic counseling were found to be efficient as the nonpharmacologic treatment of antipsychotic-induced metabolic syndrome. Few pharmacological treatments were proven effective against weight gain in this patient population. The risk of metabolic syndrome induced by antipsychotics should be early recognized and closely monitored. Primary and secondary prevention of metabolic syndrome or onset of its feature might help reduce the risk of death for patients using antipsychotics.

31 May 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
Carlotta LunghiCarlotta Lunghi
Carlotta Lunghi
MDMichèle Dugas
Michèle Dugas
JLJacinthe Leclerc
Jacinthe Leclerc
EPElisabetta Poluzzi
Elisabetta Poluzzi
CMCathy Martineau
Cathy Martineau
ALAnnie LeBlanc
Annie LeBlanc
Introduction Antidepressant drugs are the most frequently prescribed medication for mental disorders. They are also used off-label and for non-psychiatric indications. Prescriptions of antidepressants have increased in the last decades, but no systematic review exists on the extent of their use in the community. Methods and analysis We will conduct a systematic review to estimate the prevalence of antidepressant use in the community. We will search for studies published from 1 January 2010 in the Embase and MEDLINE databases using a combination of controlled vocabulary and keywords adjusted for each database without any language restriction. The main inclusion criterion is the presence of prevalence data of antidepressant utilization. Thus, we will include all studies with a descriptive observational design reporting the prevalence of antidepressant use in the community. Study selection (by title/abstract and full-text screening) and data extraction for included studies will be independently conducted by pairs of reviewers. We will then synthesize the data on the prevalence of antidepressant use in individuals living in the community. If possible, we will perform a meta-analysis to generate prevalence-pooled estimates. If the data allows it, we will conduct subgroup analyses by antidepressant class, age, sex, country and other sociodemographic categories. We will evaluate the risk of bias for each included study through a quality assessment using the Joanna Briggs Institute Critical Appraisal tool: Checklist for Studies Reporting Prevalence Data. DistillerSR software will be used for the management of this review. Ethics and dissemination Ethical approval is not required for this review as it will not directly involve human or animal subjects. The findings of our systematic review will be disseminated through publications in peer-reviewed journals, the Qualaxia Network (https://qualaxia.org), presentations at international conferences on mental health and pharmacoepidemiology, as well as general public events. PROSPERO registration number CRD42021247423.

27 June 2023 in Journal of Applied Biomedicine
Verified
Journal Article
Open access
PDF file
PPPallavi Pradhan
Pallavi Pradhan
MLMaude Lavallée
Maude Lavallée
SASamuel Akinola
Samuel Akinola
FGFernanda Raphael Escobar Gimenes
Fernanda Raphael Escobar Gimenes
ABAnick Bérard
Anick Bérard
JLJacinthe Leclerc
Jacinthe Leclerc
Background: The core motive of pharmacovigilance is the detection and prevention of adverse drug reactions (ADRs), to improve the risk-benefit balance of the drug. However, the causality assessment of ADRs remains a major challenge among clini...

11 April 2020 in Drugs
Verified
Journal Article
Closed access
PDF file
JLJacinthe Leclerc
Jacinthe Leclerc
MTMagalie Thibault
Magalie Thibault
JGJennifer Midiani Gonella
Jennifer Midiani Gonella
CBClaudia Beaudoin
Claudia Beaudoin
JSJohn Sampalis
John Sampalis

28 November 2024 in International Journal for Quality in Health Care
Verified
Journal Article
Open access
MLMaude Lavallée
Maude Lavallée
SCSonia Corbin
Sonia Corbin
PPPallavi Pradhan
Pallavi Pradhan
LGLaura Blonde Guefack
Laura Blonde Guefack
MTMagalie Thibault
Magalie Thibault
JLJacinthe Leclerc
Jacinthe Leclerc
Background: An adverse event (AE) is any undesirable medical manifestation in an individual who has received pharmacological treatment. To be considered serious (SAE), it needs to meet minimally one of the severity criteria by Health Canada. The most recent data (2006) suggested that AEs were underreported (<6%) to health authorities. In Canada, since the implementation of Vanessa’s Law (2019), hospitals are required to report SAEs; however, this law remains relatively unknown. The objectives of the study were: (i) to document the incidence of any AE and SAE over time in a ‘real’ clinical context, (ii) to quantify SAEs reported to Health Canada, and (iii) to assess whether Vanessa’s Law has led to an increase in mandatory reporting to Health Canada. Methods: We carried out a descriptive retrospective study at the Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, including 500 patients hospitalized between 1 January 2018 and 31 December 2021 and randomized into 4 cohorts (125 patients/year). Descriptive and comparative analyses were performed. Results: The characteristics of the cohorts were: 43.6% women; median age: 69 years (min–max: 21–96 years), number of comorbidities: 4 (1–12). During their hospitalization, patients consumed 18 different drug products (2–56) and the median of observed SAEs/patients was 0 (0–10) (total: 302). The overall percentage of SAEs reported to Health Canada was 0%, before and following the implementation of Vanessa’s Law. Conclusion: According to 500 electronic medical records, SAEs were underreported to Health Canada, even after the implementation of Vanessa’s law.

13 September 2022 in Heliyon
Verified
Journal Article
Open access
SOSarah O'COnnor
Sarah O'COnnor
CBClaudia Blais
Claudia Blais
MMMiceline Mésidor
Miceline Mésidor
DTDenis Talbot
Denis Talbot
PPPaul Poirier
Paul Poirier
JLJacinthe Leclerc
Jacinthe Leclerc
The progression of complications of type 2 diabetes (T2D) is unique to each patient and can be depicted through individual temporal trajectories. Latent growth modeling approaches (latent growth mixture models [LGMM] or latent class growth analysis [LCGA]) can be used to classify similar individual trajectories in a priori non-observed groups (latent groups), sharing common characteristics. Although increasingly used in the field of T2D, many questions remain regarding the utilization of these methods. To review the literature of longitudinal studies using latent growth modeling approaches to study T2D. MEDLINE (Ovid), EMBASE, CINAHL and Wb of Science were searched through August 25th, 2021. Data was collected on the type of latent growth modeling approaches (LGMM or LCGA), characteristics of studies and quality of reporting using the GRoLTS-Checklist and presented as frequencies. From the 4,694 citations screened, a total of 38 studies were included. The studies were published beetween 2011 and 2021 and the length of follow-up ranged from 8 weeks to 14 years. Six studies used LGMM, while 32 studies used LCGA. The fields of research varied from clinical research, psychological science, healthcare utilization research and drug usage/pharmaco-epidemiology. Data sources included primary data (clinical trials, prospective/retrospective cohorts, surveys), or secondary data (health records/registries, medico-administrative). Fifty percent of studies evaluated trajectory groups as exposures for a subsequent clinical outcome, while 24% used predictive models of group membership and 5% used both. Regarding the quality of reporting, trajectory groups were adequately presented, however many studies failed to report important decisions made for the trajectory group identification. Although LCGA were preferred, the contexts of utilization were diverse and unrelated to the type of methods. We recommend future authors to clearly report the decisions made regarding trajectory groups identification.